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Abstract: Fear is a fundamental evolutionary process for survival. However, excess or irrational
fear hampers normal activity and leads to phobia. The amygdala is the primary brain region
associated with fear learning and conditioning. There, Rho GTPases are molecular switches that act as
signaling molecules for further downstream processes that modulate, among others, dendritic spine
morphogenesis and thereby play a role in fear conditioning. The three main Rho GTPases—RhoA,
Rac1, and Cdc42, together with their modulators, are known to be involved in many psychiatric
disorders that affect the amygdala′s fear conditioning mechanism. Rich2, a RhoGAP mainly for Rac1
and Cdc42, has been studied extensively in such regard. Here, we will discuss these effectors, along
with Rich2, as a molecular switch for fears, especially in the amygdala. Understanding the role of
Rho GTPases in fear controlling could be beneficial for the development of therapeutic strategies
targeting conditions with abnormal fear/anxiety-like behaviors.
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1. Introduction
All mammals exhibit fear and anxiety as part of their evolutionary survival strategy. Fear or
adaptive anxiety refers to a state with increased alertness and vigilance, enabling the individual to
perform multiple defensive behaviors. However, excessively disproportionate fear with no trigger can
give rise to anxiety disorders and phobia [1]. Over 28% of adults experience or exhibit some form of
anxiety in their lifetime [2]. Evidence suggests that human neuropsychiatric disorders related to anxiety
arise from abnormal fear learning mechanisms and unusual activity patterns in cerebral networks [3,4].
Various animal models have been developed to study anxiety and fear. In general, fear learning is
well conserved among species, and studies from animal models greatly help understand the human
condition [5].
Different kinds of tests have been designed to evaluate anxiety-related behaviors in rodents. These
include the elevated plus maze (EPM), open field test (OF), light-dark box (LDB), and free choice
exploratory (FCE) paradigm. In general, the tests are designed to assess active avoidance of potentially
unsafe, dangerous, or predatory areas; like the closed arm of the EPM vs. the open arm, the center
region of the OF vs. the corners, or the dark box in the LDB vs. the lit compartment [2,6]. Rodents
that are more anxiety-prone tend to avoid open or brightly-lit areas in these tests, mimicking the
human condition.
The amygdala is the main region for fear processing and fear memory [7]. Different subregions
of the amygdala have been associated with different phobias [8]. Additionally, neuropsychiatric
conditions, like autism spectrum disorders (ASD) and post-traumatic stress disorders, have been linked
with abnormal amygdala activity [9,10]. For example, amygdala hypo-perfusion has been detected via
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positron emission tomography (PET) in Phelan McDermid syndrome, a disorder frequently associated
with ASD [11].
The Rho family of small GTPases is a subfamily of Ras small GTPases. Rho GTPases are
guanosine-dependent molecular switches. They are involved in numerous cellular processes ranging
from cell division, differentiation, and migration to immunological and neurobiological processes [12].
Because of their ubiquitous nature and usefulness, the expression and activity of Rho GTPases
are tightly regulated. Disruption in a homeostatic situation can cause many diseases like cancer,
neurological disorders, and autoimmune diseases [13]. Importantly, Rho GTPases are also expressed in
the amygdala. There, Rho GTPases and their effectors [14] participate in biological processes regulating
fear conditioning in relation to neuropsychiatric disorders [15,16].
2. The Amygdala Is the Fear Center in the Brain
From the evolutionary point of view, fear of threatening stimuli is a prerequisite for survival and
environmental adaptation. In addition to innate fear, learned fear is also vital for defensive behavior.
In the laboratory, Pavlovian fear conditioning is widely used as a measure for fear conditioning in
rodents, where animals are trained to associate a neutral sensory stimulus or conditioned stimulus
(CS) with an aversive event or unconditional stimulus (US). After several rounds of training, the CS
alone can generate a behavioral or autonomic response (like freezing or increased heart rate) without
the US [17]. Decades of works have established the amygdala, hippocampus, and prefrontal cortex
as the major brain regions associated with fear learning. However, the amygdala is the critical brain
region for fear memory [1,18].
Anatomically, the amygdala is divided into several nuclei—the basolateral (BLA) and central
(CEA) nuclei [19]. The BLA is further subdivided into basolateral (BA), basomedial (BM), and lateral
amygdala (LA). The CEA can be divided into a lateral (CEl) and medial (CEm) part (Figure 1). There are
also intercalated cell masses (ICMs). The LA is the primary point of entry for sensory inputs, whereas
the CEm is the primary source of projections to the brainstem. However, the transfer from LA to CEm
is gated by other amygdala regions and their distinct cell types. The BLA receives sensory information
from the thalamus and prefrontal cortex via the LA and sends signals to the CEA, where further
processing occurs.
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subdivided into basolateral amygdala (BLA) and central nuclei (CEA). The BLA is further divided into
basolateral (BA) and lateral amygdala (LA). The CEA is subdivided into a lateral (CEl) and medial
(CEm) part. Broadly, the LA is the point of sensory input, and CEm is the main point of output to the
brain stem.
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The majority of BLA neurons are spiny glutamatergic neurons (with a minority of GABAergic
interneurons) [20]. CEl and CEm mainly contain GABAergic neurons. The ICMs are small cell clusters
and consist of more dopamine type-1 and µ-opioid-receptor expressing cells [21]. The sensory and
synaptic outputs in the amygdala heavily depend on GABAergic inhibitory outputs. They are crucial
to anxiety-related fear memory, and many GABA receptor agonists are used as anxiolytic agents [22].
There are high intrinsic and extrinsic connectivities of the amygdala [23], controlling which
synapses will be strengthened upon exposure to fear conditioning stimuli [24]. Many studies in the
1990s have established the LA as the principle synaptic plasticity site of Pavlovian fear [25]. Optogenetic
studies have revealed pre- and postsynaptic activity for the generation of long-term potentiation (LTP)
in the LA [26,27]. Accordingly, alteration of thalamic-amygdala synapses affects fear memories [28].
Intriguingly, critical molecular mechanisms of synaptic plasticity are regulated by Rho GTPases.
3. Rho GTPases and Their Regulation
The Ras superfamily consists of five smaller subfamilies—Ras, Rho, Ran, Rab, and Arf; based on
their sequence, structure, and function [29]. The Rho subfamily has almost 20 members, and they are
mostly associated with actin organization and gene expression. Rho GTPases are active when they are
GTP bound and inactive when they are GDP bound. This switch from an active to inactive state (and
vice versa) is modulated by many GTPase effectors, namely guanosine nucleotide exchange factors
(GEFs), GTPases activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs)
(Figure 2). The effectors control the GTPases′ activity via several mechanisms: conformational change,
translocation to membranes, and relief of auto-inhibitory intramolecular interactions [30].
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i r 2. The Rho GTPases act s molecular switches in the cellular environment. They are active when they
are GTP bound and inactive whe they are GDP bound. A s and GEFs do the exchanges between GTP
and GDP. When ot active, t e Rho GTPases remain in the cytoplasm using GDIs. Via geranylgeranylation
using the enzyme GGT, they appear on the surface of the plasma membrane. (GDP-guanosine
diphosphate, GTP-guanosine triphosphate, GAP-GTPase activating protein, GEF-guanosine activating
factors, GDI-guanosine dissociation inhibitor, GGT-geranylgeranyl transferase).
Rho GTPases are activated by GEF proteins and inactivated by GAPs. A GEF binds with GDP-bound
inactive Rho GTPases and forms a low-affinity complex. After nucleotide dissociation, the low-affinity
complex is converted into a nucleotide-free/GEF high-affinity complex via conformational change.
Upon GTP binding, the complex is converted again into a low-affinity complex, and eventually, the GEF
is released [31,32]. The Rho GTPase subfamily has more than 66 GAPs, further increasing control of
their activity [33]. Even though each Rho GTPase has intrinsic hydrolysis activity, the GAP proteins
accelerate it by several orders of magnitude, which ensures a rapid turn-over [34]. Thus, via hydrolysis
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of GTP to GDP, GAPs inactivate the GTPases and prevent them from being constitutively active. For the
interaction between Rho GTPases and GAPs/GEFs, the proteins have to be membrane-bound on the cell
surface. The GDIs give another level of control of GTPase actions. The GDIs bind with the inactive
forms of small GTPases and sequester them inside the cellular cytoplasm. They are unique to only Rho
and Rab subfamily of Ras proteins [35].
The most well-known and best characterized Rho GTPase members are RhoA (Ras homologous
member A), Rac1 (Ras-related C3 botulinum toxin substrate 1), and Cdc42 (cell division cycle 42).
Genomic duplication of RhoA gave rise to RhoC, while RhoB is a retrotransposon of RhoA. There are
also Cdc42-like (for example, TC10 and TCL) and Rac1-like (Rac2 and Rac3) proteins [36]. Each member
activates some kinases or other signaling proteins that usually mediate actin dynamics. Through
this, Rho GTPases have many roles in neuronal differentiation, migration, polarity establishment,
morphogenesis, axon growth and guidance, and neurite outgrowth [37]. Rho GTPases affect various
actin-binding and modulating proteins. For example, both Cdc42 and Rac1 can activate PAK1
(p21 activated kinase), LIMK1 (LIM kinase 1), and cofilin [38]. On the other hand, the main effector for
RhoA is ROCK (Rho-associated coiled-coil containing protein kinase) [39].
4. Rho GTPases in Synaptic Spine Plasticity
The tiny, actin-rich protrusions on the surface of neuronal dendrites are dendritic spines, which
harbor the postsynaptic density of excitatory synapses and receive synaptic inputs [40–42]. Dendritic
spines are dynamic and heterogeneous; depending on the synaptic strength, they can undergo size
changes, a process termed spine morphogenesis [43]. There are different subtypes of the spine in
terms of shape and activity. A “mature” spine usually has a short neck with a big head, mimicking a
mushroom’s shape. An “immature” spine usually has a long neck. These spines are referred to as
filopodia or thin shaped [44].
Due to the differences in shape and size, different spines can harbor a different set of proteins
in their postsynaptic density (PSD). The structural components of the PSD include different types of
metabotropic and ionotropic glutamatergic receptors (e.g., AMPA and NMDA receptors), actin effectors,
transporters, ion channels, and various scaffolding proteins (like Shank, PSD95, Homer-1) [45,46].
The scaffolding proteins are the central hub in the PSD, and they bind with receptors as well as Rho
GTPases. This establishes the GTPases and their effectors at the heart of spine morphogenesis [47].
They can participate in this process via their effect on actin polymerization. The effects of three main
Rho GTPases on spine morphogenesis are summarized in Table 1. The downstream effectors of the
main Rho GTPases and their roles in spine morphogenesis are illustrated in Figure 3.
Table 1. Role of Rho GTPases on spine morphogenesis in vivo and in vitro.
GTPase Study Model Study Findings Ref.
RhoA Neuronal culture Inhibits dendritic growth and dynamics;constitutive overexpression leads to spine loss [48]
Rac1
Neuronal culture Promotes dendritic growth and dynamics [48]
Hippocampal slice culture Overexpression of dominant-negative Rac1reduces spine density [49]
Conditional knock-out (alpha
CaMKII promoter, deletion in the
postnatal hippocampus)
Reduction in Rac1 activity and spine density,




Neuronal culture Promotes dendritic growth and dynamics [48]
Conditional knock-out (alpha
CaMKII promoter, deletion in
postnatal forebrain)
Spine density of hippocampal CA1 reduced,
remote memory recall was impaired [52]
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Figure 3. Rho GTPases in spine morphogenesis. A thin, immature spine can stabilize using synaptic
potentiation and Rac1/Cdc42 signaling. Using the downstream signaling and actin effectors, both Rac1
and Cdc42 can stabilize an immature spine resulting in a mature mushroom-shaped spine. The RhoA and
synaptic depression do the opposite. The RhoA signaling pathway, along with ROCK, can destabilize
the spine and give it a filopodia shape. (Rac1: Ras-related C3 botulinum toxin substrate 1, Cdc42: Cell
division control protein 42 homolog, RhoA: Ras homolog gene family, member A, PAK1: p21-activated
kinase 1, LIMK1: LIM domain kinase 1, ROCK: Rho-associated, coiled-coil-containing protein kinase).
Actin can remain in either monomeric G (globular) state or polymeric F (filamentous) state.
The actin effectors change the equilibrium between these two states [53,54]. In the case of excitatory
signal input or long-term potentiation (LTP), the equilibrium is shifted more towards F actin and, hence,
the spine enlargement [55]. In the case of inhibitory input or long-term depression (LTP), the opposite
happens, and the spine shrinks [56] (Figure 3). The change in spine size is accompanied by membrane
polarization/depolarization, synaptic receptor activation/deactivation, and calcium influx/efflux [57].
Geranylgeranultransferase I (GGT) is a protein prenyltransferase that catalyzes the attachment of
a prenyl lipid anchor to the carboxy-terminal of various proteins, including RhoA, Rac1 and Cdc42.
It facilitates the tethering of that protein on the plasma membrane [58]. In line with the roles of the
Rho GTPases, GGT promotes dendritic morphogenesis in vitro [59]. Inhibition of GGT and, thus,
prevention of Rac1 activation on the cell surface decreases dendritic spine density in several brain
regions [60].
Aberration in spine morphogenesis has been associated with neuropsychiatric disorders for a
long time [61,62]. For example, an analysis of the post-mortem brain of ASD patients showed altered
spine morphology [63]. Additionally, in many forms of intellectual disability, disruptions in spine
morphogenesis have been reported [61]. Thus, Rho GTPases in spine morphogenesis may significantly
contribute to such disorders, and altered fear/anxiety behavior in parallel.
5. Rho GTPases and Fe r Conditioning in the Amyg ala
The role of Rho GTPases in fear conditioning and consolidation is not well studied so far. However,
evidence emerged for their essential role in these processes. For example, prenatal exposure to
valproic acid induces anxiety-like behavior and changes the gene expression of Rho GTPases in the
amygdala of mice [64]. Cat odor can induce anxiety-like behavior in rats. This reaction is embedded
ethologically in their genetic memory. When male rats are exposed to cloth containing cat urine,
they show anxiety-like behavior and try to avoid the cloth which suppresses their exploratory home
cage activity [65]. This odor stimulus avoidance is accompanied by gene expression changes, especially
the gene encoding RhoGAP 4 (Arhgap4) and RhoGEF KIAA0377.
Some of our understandings on how Rho GTPases work in the amygdala come from drug
addiction and withdrawal studies. Using a conditional place aversion model, it was established that
actin polymerization in the amygdala is responsible for forming aversive memory after morphine
withdrawal [66]. A further study showed that the actin polymerization is mediated by the RhoA-ROCK
signaling pathway and requires NMDA receptor activation [67]. The Rho-ROCK pathway in the
Cells 2020, 9, 1972 6 of 19
lateral amygdala is also part of the nitric oxide driven retrograde signaling in the context of Pavlovian
fear conditioning [68]. In addition, the administration of the stress hormone corticosterone on
amygdaloid cell lines resulted in alteration in serotonin receptor types, and changes in RhoA and
Cdc42 expression [69]. Decreased levels of Cdc42 in the forebrain (including the amygdala) lead to
impairment in LTP formation and remote memory recall [52].
Additionally, Rac1 has been studied to some extent in the context of fear conditioning. Martinez et al.
reported that Rac activation is increased after associative fear learning, which can be blocked using an
NMDA receptor channel blocker [70]. Further, the extinction of contextual fear memory is mediated
by Rac1 downregulation [71]. Before training, activation of cerebral RhoA and Rac1 enhances
fear memory [72]. Rac1 inhibition using NSC23766 in the BLA after memory retrieval disrupted
the reconsolidation of auditory fear memory [73]. Moreover, a mouse model was generated with
conditional deletion of Rac1 in the BLA using an alpha CaMKII promoter and the stereotaxic application
of AAV encoding Cre recombinase. This conditional deletion of Rac1 in excitatory neurons in the BLA
impaired both short- and long-term memories [74]. Using optogenetics techniques, Das et al. have
shown that activation of Rac1 in the amygdala induces PAK1 phosphorylation and inhibits long-term
(but not short-term) memory formation [75]. Rac1 also has a role in the extinction of aversive memory.
The knock-down of Rac1 via shRNA in the ventromedial prefrontal cortex suppressed conditioned
place aversion [76]. Together, these findings indicate that Rho GTPases and some of their modulators
that are expressed in amygdaloid brain regions (Table 2) are important players in fear-related processes
mediated by the amygdala.
Table 2. Expression of Rho GTPases and their modulators in amygdala subregions in rodents.
GTPase BLA Expression CEA Expression Ref.
RhoA + (in all parts of the amygdala) [67]
Rac1 + not reported [74,77]
Cdc42 + * -
Kalirin + CEl and CEm [78]
Rich2 + [79]
BCR + * [80]
Dock9 + * [80]
Trio + * [80]
Wfs1 + [81]
Auts2 + * [80]
Dock4 + * [80]
RICS + [82]
RAPGEF6 + [83]
Oligophrenin 1 ubiquitous (whole brain) [84]
MEGAP + [85]
* expressed in humans.
6. The Critical Role of Rich2 in Fear Modulation
Rich2 (RhoGAP interacting with CIP4 homolog 2) was first identified as an interaction partner
of Shank3 (SH3 and multiple ankyrin repeat domains 3), a very well-characterized gene associated
with ASD [47]. Rich2 has an N-terminal BAR (Bin/Amphiphysin/Rvs) domain, RhoGAP domain,
a proline-rich domain, and a C-terminal STAL motif. Yeast two-hybrid assays showed that using the
STAL motif, Rich2 interacts with the PDZ domain of Shank3 [86]. Rich2 is expressed in different brain
regions, including the hippocampus, cerebellum, cortex, and amygdala, and localized to excitatory
synapses throughout different ages [87]. In rats, Rich2 is located on 10q23 and codes for an 818 amino
acid containing protein with 22 exons and 21 introns [88].
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6.1. Rich2 Deletion Induces Specific Behavioral Changes in Mice
The Rich2 knock-out mice have been studied extensively using different behavioral tests [79,86].
Because of the interaction with Shank3, it was anticipated that Rich2 deletion might result in some
autism features. Indeed, the Rich2 knock-out mice showed an increase in stereotypic behavior.
In addition, the deletion of Rich2 impaired motor learning in knock-out animals. Most interestingly,
specific impairments in the novel object recognition test were observed. When there was an object
present in the open field arena, the knock-out mice significantly preferred the non-object zone over the
object zone. Even when the object color or shape changes, i.e., mimics a four-legged animal, the results
remained the same. Object phobia is rarely reported in animal models. To our knowledge, only mice
lacking or over-expressing Neuroserpin, a serine protease inhibitor, show a similar phenotype [89].
6.2. Rich2 Deactivates Different Rho GTPases in Different Brain Regions
The expression and activity of Rho GTPases are tightly controlled via differential and spatial
expression. A large number of GEF, GAP, and GDI proteins also help along this line. Usually, GTPase
modulators interact with both Rac1 and Cdc42 [90,91]. However, RhoGEF H1 can interact with RhoA
and Rac1 [92], while the GEF proteins Vav and Vav2 bind all three of the main Rho GTPases [90,93]. In a
cell-free assay, the RhoGAP Rich2 exerts its GAP activity on RhoA, Rac1, and Cdc42 [94]. However,
in vivo, Rich2 has been shown to activate Rac1 and Cdc42 in the hippocampus, but RhoA in the
amygdala [79,86,87]. In line with this, in hippocampal cell culture, Rich2 deletion leads to over-activation
of Rac1. Usually, RhoA and Rac1 have the opposite effect of spine morphogenesis [95]. Rac1 promotes
spine formation, while RhoA inhibits the process [96]. Therefore, the brain-region specific activity of
Rich2 is crucial to modulate spine morphogenesis in different directions in different brain regions.
6.3. Spine Morphology in Rich2 Knock-Out Animals
Rich2 possesses an N-BAR domain. Its function is associated with the induction of receptor-mediated
membrane curvature [97], a process required for vesicle recycling. In line with this, it has been shown
that Rich2 deletion alters the PSD composition [79,86], especially for the AMPA receptor GluA4 and
NMDA receptors—GluN1 and GluN2A that are regulated by vesicle trafficking. The spine morphology
was also altered in the hippocampus and amygdala of the knock-out animals. In the hippocampus,
the spine area was increased, and there was a shift from the mature mushroom spine to multi-lobbed
spines. Electron microscopy revealed an increase in PSD density per optic field without any alteration
in PSD length and width. Such alteration can be well explained in terms of the over-activation of Rac1.
Further, the downstream actin effector for Rac1 mediated signaling was shown to be EPS8, an actin
capping protein [98]. Therefore, the formation of F actin from G actin was significantly faster in the
knock-out animals. Thus, the deletion of Rich2 over-activates Rac1 in the hippocampus, and drives the
spine morphology to mature spines via recruiting EPS8.
However, in the amygdala, Rich2 deletion over-activates RhoA. Rac1 and RhoA have an
antagonistic effect on spine morphogenesis. In line with this, the amygdala′s spine morphology
was driven towards an immature filopodia shape, without altering the spine density. Furthermore,
the equilibrium between G and F actin was shifted in the direction of G actin. Thus, Rich2 deletion
affects different brain regions in different ways, directed by the Rho GTPase it acts on.
6.4. Deletion of Rich2 Affects the Immediate-Early Gene Expression in the Amygdala
Activation of amygdala neurons alters the expression of immediate early genes. One of such
genes is cFos. The cFos positive puncta in the BLA of the amygdala of the Rich2 knock-out mice
were increased compared to wild-type mice [79]. RhoA can activate cFos in non-neuronal cells [99].
The same holds for neuronal cells in the amygdala as well. Thus, normally, Rich2 may keep amygdala
activation in check by stabilizing excitatory synapses and reducing cFos activation in the BLA. Findings
from the Rich2 knock-out animals are summarized in Figure 4.
Cells 2020, 9, 1972 8 of 19
Cells 2020, 9, x FOR PEER REVIEW 8 of 19 
 
 
Figure 4. The effect of Rich2 deletion in different brain regions. Rich2 deletion affects different brain 
regions differently. Rich2 deletion increases stereotypic behavior and object phobia. Knock-out of 
Rich2 in the hippocampus shifts the spine morphology towards multi-lobbed spines, along with 
increased Rac1 signaling, whereas in the amygdala, the spines are shifted towards filopodia-shaped 
spines, along with an increase in RhoA signaling. There are also alterations in F and G actin 
equilibrium, immediate early gene expression, and synaptic signaling. 
6.5. Shank3-Rich2 Interaction in the Context of Fear Learning 
Shank3 is one of the most studied genes associated with ASD. Several mouse models have been 
generated to understand the pathophysiology of the disease, including mice with partial deletion and 
point mutations [100–103]. For most of the models, autism-related phenotypes were investigated 
extensively. Interestingly, some of the models also exhibited abnormal anxiety, fear memory, and 
object recognition. For example, a mouse model lacking exon 4–9 of Shank3 exhibited object 
recognition deficits [104]. Another study with full Shank3 deletion showed increased anxiety-like 
behavior of knock-out and heterozygous animals compared to wild-type animals [105]. Another 
group reported impaired contextual fear learning in the Shank3 knock-out mouse model [106]. 
However, to the best of our knowledge, no study has been carried out to specifically investigate the 
function of Shank3 in the amygdala even though Shank3 has been reported to be expressed there 
[107].  
The functional interaction between Shank3 and Rich2 has been studied extensively in vitro 
[94,108]. Upon LTP induction, their interaction is increased. Mutated Rich2 without Shank3 
interacting motif, is not well tolerated in hippocampal culture and long-term application of this 
version of Rich2 on hippocampal neuronal culture was deleterious for cell health. Shank3 without 
PDZ domain and, thus, unable to bind Rich2, can no longer increase receptor recycling upon cLTP 
induction [108]. This hints at the importance of the Shank3-Rich2 interaction for LTP mediated 
receptor recycling. The Rich2 knock-out mouse model showed decreased Shank3 expression in the 
hippocampus, which was not compensated by other Shank isoforms [86]. In addition to Rich2, 
Shank3 has other interaction partners linking Rho GTPase and Shank3 signaling pathways. Beta-PIX, 
a RhoGEF for Rac1 and Cdc42, can interact with the PDZ domain of Shank3 [88]. The downstream 
signaling molecule for Shank3-beta PIX is PAK, which connects Shank3 to actin remodeling [51]. 
IRSp53 (insulin receptor tyrosin substrate kinase 3) interacts with Shank3 with its proline-rich regions 
and is a downstream signaling molecule of Cdc42 [90]. There are significant overlaps between Shank3 
mediated structural organization of dendritic spine, and Rho GTPase influenced actin dynamics. 
Thus, Shank3/Rich2 interactions may be critical for Rho GTPase mediated fear regulation in the 
amygdala. 
7. Rho GTPases and Fear Modulation in Neurological/Neuropsychiatric Disorders with Anxiety 
and Phobia as Comorbidities 
Figure 4. The effect of Rich2 deletion in different brain regions. Rich2 deletion affects different brain
regions differently. Rich2 deletion increases stereotypic behavior and object phobia. Knock-out of Rich2
in the hippocampus shifts the spine morphology towards multi-lobbed spines, along with increased
Rac1 signaling, whereas in the amygdala, the spines are shifted towards filopodia-shaped spines, along
with an increase in RhoA signaling. There are also alterations in F and G actin equilibrium, immediate
early gene expression, and synaptic signaling.
6.5. Shank3-Rich2 Interaction in the Context of Fear Learning
Shank3 is one of the most studied genes associated with ASD. Several mouse models have been
generated to understand the pathophysiology of the disease, including mice with partial deletion
and point mutations [100–103]. For most of the models, autism-related phenotypes were investigated
extensively. Interestingly, some of the models also exhibited abnormal anxiety, fear me ory, and object
recognition. For example, a ouse model lacking exon 4–9 of Shank3 exhibited object rec gnition
deficits [104]. Ano her study with full Shank3 de etion show d i creased a xi ty-like behav or of
knock-out and heterozygous animals c mp red to wild-type anima s [105]. Another group reported
impaired contextual fe r learni g in the Shank3 knock-out mouse model [106]. However, to the best of
our knowledge, no study has been carried ut to specifically investigate the function of Shank3 in the
amygdala even though Shank3 has been reported to be expressed there [107].
The functional interaction between Shank3 and Rich2 has been studied extensively in vitro [94,108].
Upon LTP induction, their interaction is increased. Mutated Rich2 without Shank3 interacting motif,
is not well tolerated in hippocampal culture and long-term application of this version of Rich2 on
hippocampal neuronal culture was deleterious for cell health. Shank3 without PDZ domain and,
thus, unable to bind Rich2, can no longer increase receptor recycling upon cLTP induction [108].
This hints at the importance of the Shank3-Rich2 interaction for LTP mediated receptor recycling.
The Rich2 knock-out mouse model showed decreased Shank3 expression in the hippocampus, which
was not compensated by other Shank isoforms [86]. In addition to Rich2, Shank3 has other interaction
partners linking Rho GTPase and Shank3 signaling pathways. Beta-PIX, a RhoGEF for Rac1 and Cdc42,
can interact with the PDZ domain of Shank3 [88]. The downstream signaling molecule for Shank3-beta
PIX is PAK, which connects Shank3 to actin remodeling [51]. IRSp53 (insulin receptor tyrosin substrate
kinase 3) interacts with Shank3 with its proline-rich regions and is a do nstream signaling molecule
of C c42 [90]. Th re are sig ificant ov rlaps between Shank3 mediated structural orga ization of
dendritic spine, and Rho GTP se influenced actin dynamics. Thus, Shank3/Rich2 interactio s ay be
critical for Rho GTPase mediated fear regulation in the amygdala.
7. Rho GTPases and Fear Modulation in Neurological/Neuropsychiatric Disorders with Anxiety
and Phobia as Comorbidities
Fear is a strong and ancient emotion. However, too much or too little or unspecified fear is not
suitable for day to day life and can often be life-threatening [109]. The fine line between fear and phobia
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is essential. Since anxiety and phobia are comorbidities in many psychiatric conditions [110,111],
animal models with a phobia can shed light on these comorbidities′ causal mechanisms. It is also
not surprising that disorders with anxiety and phobia as comorbidities have been associated with
impaired Rho GTPase signaling.
7.1. Rho GTPases in Mood Disorders
The breakpoint cluster region (BCR, chromosomal location 22q11) is significantly associated
with bipolar disorder [112]. The BCR codes for the RhoGAP protein p21rac. In addition, Dock9,
a RhoGEF for Cdc42, has also been associated with bipolar disorder [113,114]. Further, TRIO, a GEF
for RhoA, Rac1, and RhoG, has been identified as a bipolar disorder-associated gene [115]. Wolfram
disease is a form of bipolar disorder, and the causative gene is Wfs1. Aside from other brain regions,
Wfs1 protein is expressed in the amygdala [81]. In addition to memory impairment and decreased
social interactions, the Wfs1 knock-out animals also exhibited increased fear behavior. It was shown
that the deletion of Wfs1 leads to the downregulation of Cdc42ep5, one of the targets of Cdc42.
Furthermore, the conditional knock-out mouse model of RhoGAP alpha2-chimaerin with a deletion
of alpha2-chimaerin from adult hippocampus using a nestin promoter, exhibited both anxiety and
depression-like behavior [116]. GIMP (Gem interacting protein) is a novel RhoGAP, which has also
been associated with depression [117].
7.2. Rho GTPases in Autism Spectrum Disorders
ArhGEF10, a GEF for RhoA, has been characterized in relation to ASD. ArhGEF10 is widely
expressed in different brain regions. Apart from ASD-related behaviors such as social impairments,
ArhGEF10 knock-out mice exhibited altered anxiety levels [118]. Another gene that has been associated
with ASD, epilepsy, dyslexia, attention deficit hyperreactivity disorder (ADHD), and schizophrenia is
Autism susceptibility candidate gene 2 (Auts2) [119,120]. Auts2 is highly expressed in the cerebral
cortex, hippocampus, and cerebellum [121]. Auts2 activates the Rac1 signaling pathway and promotes
neurite extension, neuronal migration, and induces lamellipodia [122]. The Auts2 heterozygous mice
exhibited ASD-like behaviors but also decreased anxiety in the open field and elevated plus maze,
a decrease in freezing response while showing higher response to lower nociceptor stimuli-indicating
defective auditory fear conditioning and higher acoustic startle response [120].
Dock4 or dedicator of cytokinesis 4 is a Rac1 GEF located in Autism susceptibility locus 1
(Auts1) [123]. This protein is highly expressed in the hippocampus, cortex, and cerebellum [124].
Dock4 heterozygous mice showed defective social behaviors [125]. The complete knock-out mouse
model manifested impaired social novelty preference, abnormality in vocalizations, and elevated
anxiety [125]. Moreover, ArgGAP32, known as RICS, p250RhoGAP, or Grit, is associated with ASD [126].
ArhGAP32 can act as a GAP for all three major GTPases [127,128]. This GAP protein is abundant in
the brain including in the amygdala [82]. Knock-out mice lacking all isoforms of ArhGAP32 show
abnormal cued fear-learning memory, impaired motor coordination, and ASD-related behaviors such
as increased repetitive behavior, and reduced behavioral flexibility [129,130].
7.3. Rho GTPases in Schizophrenia (SCZ)
Cdc42 was found to be upregulated in the prefrontal cortex of schizophrenic patients [131] and
several other Rho effectors have been reported to be associated with schizophrenia, such as Kalirin,
known as ArhGEF24, ArhGEF11, ArhGAP18, ArhGAP33, Myosin lXb, and Chimerin 2 [15,132,133].
Nevertheless, they are yet to be studied in animal models. RAPGEF6 is a known schizophrenia-associated
gene and is also linked to intellectual disability. It works as a GEF protein for RAP GTPases. The deletion
of RAPGEF6 reduced fear conditioning and anxiolysis and led to less neural activation in the amygdala
as measured by cFOS phosphorylation [83]. There was also a reduction in spine density and primary
dendrite number in the hippocampus, along with enhanced LTP in cortico-amygdala synapses.
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7.4. Rho GTPases in Intellectual Disability (ID)
Oligophrenin 1 (Ophn1) is a RhoGAP protein that can inactivate all three major Rho GTPases
without specificity in vitro. Mutations of this protein have been associated with ASD, ID, and cerebellar
hypoplasia [134,135]. The structure of Ophn1 is similar to Rich2 to some extent. It has a BAR domain,
a PH domain, GAP domain, and proline-rich C-terminus [136]. This RhoGAP is expressed almost
ubiquitously in the brain [84]. Deletion of Ophn1 leads to a range of behavioral abnormalities like
hyperreactivity, altered spatial memory, impaired object recognition memory, and cognitive impairment,
but also a deficit in fear memory extinction [137–139]. The cAMP/PKA signaling pathway was found
to be affected in the hippocampus and amygdala of Ophn1 knock-out mice [139]. The knock-down of
Ophn1 leads to overexpression of RhoA and a decrease in spine density [84]. Similar to the interaction
between Rich2 and Shank3 [47], Ophn1 binds the scaffolding protein Homer, and this interaction is
vital for mGluR mediated signaling.
The ArhGEF9, alternatively known as collybistin, works for Cdc42 [140]; and is associated with
ID, epilepsy, anxiety, and aggression [141]. Collybistin knock-out mice show reduced exploratory
behavior and enhanced anxiety [142]. Collybistin is expressed in the BLA, and its deletion leads to loss
of inhibitory gephyrin and GABA clusters [126,140]. Moreover, ArhGAP14 (MEGAP or SrGAP3) is a
member of the Slit-Robo GTPase-activating protein subfamily and has GAP activity for Rac1 [143].
SrGAP3 is associated with ID [85,142] and ASD. It has a role in spine development and is highly
expressed in several brain regions, including the amygdala [85]. Loss of SrGAP3 disrupts LTP, impairing
learning and memory [143]. Genetic depletion of SrGAP3 leads to an increased basal level of Rac1 and
longer dendritic spines [144]. The behavioral analysis further revealed memory problems, impaired
social behavior, tics, but also altered anxiety-related behaviors, such as increased freezing time in the
fear conditioning test [144].
8. Rho GTPases as a Potential Drug Target
A number of Rho GTPases and their regulators have a functional role in the amygdala (Table 3).
Table 3. The known functions of Rho GTPases and their regulators in the amygdala.
GTPase/Regulator Function in Amygdala Association with Disease Ref.
Rac1
Extinction of contextual fear [71]
Reconsolidation of auditory fear memory [73]
Post-training activation is required for both
long-term and short-term auditory fear memory. [74]
Photoactivation of Rac1 in LA impairs fear memory. [75]
Alpha2- chimaerin
(RhoGAP) Abnormal contextual fear learning [145]
ArhGAP4 Odor stimulus avoidance [65]
MEGAP (ArhGAP14) Loss of MEGAP disrupts learning and memory ASD and ID [143]
ArhGAP32 Knock-out showed abnormal fear learning memoryand ASD-like behaviors ASD [129,130]
Oligophrenin 1
(RhoGAP)
Deletion leads to a deficit in fear memory extinction
and alteration in the cAMP/PKA pathway
ASD, ID, and Cerebellar
Hypoplasia [134,135,139]
RhoGEF KIAA0377 Odor stimulus avoidance [65]
Wfs1 Modulation of anxiety and fear Bipolar disease (Wolframdisease) [146]
TRIO (RhoGEF) Neural Development Bipolar disease [115,147]
Collybistin (ArhGEF9) Deletion leads to loss of inhibitory neurons ID, Anxiety, Epilepsy [131]
ArhGEF10 Knock-out increased norepinephrine and serotoninlevels in the amygdala ASD [118]
RAPGEF6 Deletion leads to reduced fear learning and lessneuronal activation SCZ [83]
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Thus far, the first line of treatment for many neuropsychiatric disorders with anxiety and phobias
as comorbidity, or anxiety disorders are GABA receptor antagonists like benzodiazepines [148].
However, that comes with a long list of side effects. The Rho GTPases are the downstream target of
some antipsychotic drugs already. For example, the drug GLYX-13, an NMDA modulator, activates
Rac1 (but not RhoA) to exert its anti-depressive effect [149]. Rho GTPase-related pathways are also
targeted in the oligodendrocytes and neurons by the antidepressant drug Agomelatine [150]. Paeonol
ameliorates the hippocampal neuronal morphology and depression in chronic unpredictable mild
stress rat model via compensating the effect of upregulated Rac1/RhoA [151].
In many mouse models, overexpression of Rho GTPases that were inactive due to mutation
rescued the phenotype. For example, some of the phenotypes observed after the deletion of Dock4,
i.e., reduced spine density in the hippocampus and defective social preference, was restored by
overexpression of Rac1 [125]. Over-activation of RhoA was observed in Ophn1 knock-out animals [152].
Chronic treatment with Fasudil (a clinically-approved ROCK inhibitor) restored fear memory extinction,
locomotor activity, object recognition memory, and spine morphology alterations [152].
However, there are many obstacles for targeting the small GTPases and their effectors for drug
discovery. Therefore, most Ras proteins are often considered “undruggable”. The Rho GTPases are
mainly involved in protein-protein interaction (PPI), and targeting PPI is always an enormous challenge.
There are several ways to target the activity of Rho GTPases. One strategy could be farnesyltransferase
inhibitors and geranylgeranyltransferase inhibitors that inhibit GTPases from appearing on the cell
surface. Inhibition of protein prenylation is an attractive goal for reducing the overactivation of Rho
GTPases [153]. An alternative approach could be targeting the downstream effectors, although they
often lack specificity and develop complex feedback mechanisms [154]. GEFs are easier targets than
GAPs or GDIs [12]. Examples include targeting either GTPases or GEF and inhibiting GTPase-GEF
complex formation and binding to GTPases to mimic GAP, preventing GEF activation. Numerous
small molecules have been studied to achieve these goals, but none has been proven to work flawlessly.
Nonetheless, this drug discovery field is still attractive to the pharmaceutical industry. Especially the
role of Rich2 in specific phobia-like behaviors without a generally increased anxiety could make it an
attractive drug target for specific phobias.
9. Conclusions
Impairment in fear conditioning is not just comorbidity in neurological disorders; specific phobias
may affect an individual′s day-to-day life. Therefore, understanding the process and the effect of
Rho GTPases are essential to design therapeutic strategies. Animal studies have revealed several
links between Rho GTPases and anxiety behavior, whether standing alone or in the context of other
neurological/neuropsychiatric disorders. The fact that deletion/mutation in several Rho GTPases, GAPs
and GEFs result behavior characteristic for neuropsychiatric disorders but also altered anxiety/fear
responses, or both together, points at the important role of GTPase signaling in the amygdala.
How exactly Rho GTPases regulate fear on molecular level remains to be determined and may be
complex, as illustrated by the dual role of Rich2 that interacts with Rac1 and Cdc42 in the hippocampus,
but with RhoA in the amygdala, thereby, at the same time, driving spine morphology in opposite
directions in different brain regions.
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